Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen.

1987 ◽  
Vol 5 (6) ◽  
pp. 867-874 ◽  
Author(s):  
P McLaughlin ◽  
L M Fuller ◽  
W S Velasquez ◽  
J J Butler ◽  
F B Hagemeister ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Elevated Serum ◽  
Large Cell ◽  
Cell Types ◽  
Serum Lactate ◽  
Stage Iii ◽  
Serum Lactate Dehydrogenase ◽  
Factors Affecting ◽  
Combined Modality ◽  
Abdominal Disease

From 1975 to 1982, 74 patients with stage III follicular lymphoma were treated with a combined modality protocol which included chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo), and radiotherapy to involved regions. This program resulted in a complete remission (CR) rate of 81%, a 5-year survival of 75%, and 5-year relapse-free survival (RFS) of 52% for all patients. Analysis of potential factors affecting treatment outcome revealed a significantly better CR rate for patients with small cleaved cell type (97%) than for patients with mixed (73%) or large-cell (57%) histologies. The 5-year survival was significantly better for patients with small cleaved (91%) and mixed (84%) cell types than for large cell (40%). In addition, bulky abdominal disease and elevated serum lactate dehydrogenase (LDH) were significant adverse prognostic factors for CR and for survival. Toxicity was moderate. No secondary leukemias have occurred. This combined modality regimen resulted in prolonged remission and potential cure for over half of patients who achieved CR, and is particularly encouraging for those with follicular small cleaved and mixed histologies.

Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas

Cancer ◽  
1984 ◽  
Vol 53 (7) ◽  
pp. 1478-1483 ◽  
Author(s):  
William Velasquez ◽  
Lillian M. Fuller ◽  
Kyoung K. Oh ◽  
Fredrick B. Hagemeister ◽  
Jane A. Sullivan ◽  
...  
Keyword(s):  
Combined Modality Therapy ◽  
Large Cell ◽  
Stage Iii ◽  
Combined Modality

Prognostic Significance of Elevated Serum Lactate Dehydrogenase (LDH) in Patients with Severe Sepsis

CHEST Journal ◽  
2004 ◽  
Vol 126 (4) ◽  
pp. 873S ◽  
Author(s):  
Joe G. Zein ◽  
Gregory L. Lee ◽  
Maroun Tawk ◽  
Mohammed Dabaja ◽  
Gary T. Kinasewitz
Keyword(s):  
Severe Sepsis ◽  
Lactate Dehydrogenase ◽  
Prognostic Significance ◽  
Elevated Serum ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase

scholarly journals TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL

2021 ◽  
Vol 13 (1) ◽  
pp. e2021063
Author(s):  
PIMJAI NIPARUCK
Keyword(s):  
Treatment Outcomes ◽  
Clinical Presentation ◽  
Serum Lactate ◽  
High Serum ◽  
Serum Lactate Dehydrogenase ◽  
Ki 67 ◽  
Factors Affecting ◽  
Immunohistochemistry Staining ◽  
Germinal Center B Cell ◽  
High Incidence

Background: Double-expressor lymphoma (DEL) was found accounting for 20- 30% of DLBCL. We conducted this study to analyze the survival, the clinical presentation and the factors associated with treatment outcomes in DEL-DLBCL. Methods:  A retrospective study of 291 patients diagnosed with DLBCL during January 2015 - December 2018. Results: Of the 291 patients, median age was 63 years, germinal center B cell like DLBCL (GCB) and non-GCB subtypes were found in 32% and 68%, respectively. DEL was found in 46% of 264 patients with available immunohistochemistry staining for MYC protein. Patients with DEL was significantly more common in elderly patients (p= 0.017) and non-GCB subtype (p= 0.006). High serum lactate dehydrogenase (LDH) levels and high Ki-67 index were significantly found in DEL patients than those in non-DEL patients (p= 0.024 and p= 0.04, respectively).  3y-OS and 3y-DFS in DEL patients were shorter than those in non-DEL group, 58.7% versus 78.9% (p=0.026) and 58.4% versus 67.7% (p=0.343), respectively. Independent factors affecting both OS and DFS in DEL patients were ECOG 3-4, high LDH level, extranodal involvement> 1 site, DHL, high IPI and stage III-IV. Conclusions: High incidence of DEL was observed in this study, especially in patients aged 60 years or older and non-GCB subtype. Patients with DEL showed dismal DFS and OS.

Orbital plasmacytoma as the presenting feature in multiple myeloma

2020 ◽  
pp. 112067212092995 ◽  
Author(s):  
Malavika Mani ◽  
Nirupama Kasturi ◽  
Rekha Sravya ◽  
Subashini Kaliaperumal ◽  
Debasis Gochhait
Keyword(s):  
Plasma Cells ◽  
Systemic Disease ◽  
Elevated Serum ◽  
Needle Aspiration ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Reactive Protein ◽  
Lytic Lesions ◽  
Needle Aspiration Cytology

A 50-year-old female patient presented with protrusion of the left eye for 1 month. Examination showed abaxial proptosis, restriction of extraocular movements, and elevated intraocular pressure. Computed tomography of the orbits showed soft tissue enhancing lesion in the superolateral aspect of the left orbit with lytic lesions in calvarium. Fine needle aspiration cytology of the lesion revealed a diagnosis of plasmacytoma with positive CD138 and CD38 immunohistochemical stains. Erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase were elevated. Serum protein electrophoresis revealed hypergammaglobulinemia, and bone marrow biopsy revealed 6% plasma cells. The patient was started on chemotherapy with bortezomib, dexamethasone and lenalidomide by the medical oncologist. Significant improvement in proptosis and extraocular movements noted on follow-up. Orbital myeloma may be the first manifestation of systemic disease.

Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8093-8093 ◽  
Author(s):  
Krina K. Patel ◽  
Robert Z. Orlowski ◽  
Donna M. Weber ◽  
Michael Wang ◽  
Sheeba K. Thomas ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Lactate Dehydrogenase ◽  
Prognostic Value ◽  
Intensive Therapy ◽  
Serum Lactate ◽  
Response To Therapy ◽  
Stage Iii ◽  
Serum Lactate Dehydrogenase ◽  
Survival Times ◽  
The Impact

8093 Background: In patients with symptomatic multiple myeloma, the clinical features, responses to treatment, and survival times vary. Well established predictors of survival include the International Staging System (ISS), cytogenetic abnormalities, and response to therapy. Long recognized has been the association of high serum lactate dehydrogenase (LDH) with advanced disease and shorter survival. We focused here on the impact of high LDH on staging and prognosis in order to guide the role of recent advances in therapy. Methods: We evaluated 1,247 patients with newly diagnosed, symptomatic myeloma from 10/74 to 7/11. Our goal was to determine the prognostic value of high LDH (>300 IU/L) in relation to ISS stage. We also compared the frequencies of anemia, hypercalcemia, and response to therapy in patients with high LDH with those of patients with Stage III disease and normal LDH values. Results: All 1,139 patients with normal LDH lived significantly longer than the 108 patients with elevated values (47 vs. 16 months, p <.01). LDH was elevated in 9% of all patients, but in 2%, 6%, and 18% of patients with ISS-I, II, and III disease, respectively. Their survival times were also significantly shorter than those of comparable patients in each stage with normal LDH (table). Among the 108 patients with high LDH, the frequencies of hemoglobin <8.5 g/dl (54 vs. 41%, p=.03), and serum calcium>11.5 mg/dl (41 vs. 27%, p<.01) were significantly higher than those of 292 patients with Stage III disease and normal LDH, and the frequency of response to therapy was less (40 vs. 62%, p<.01). Conclusions: Serum lactate dehydrogenase provides a convenient and dependable prognostic indicator in patients with multiple myeloma. An elevated LDH value indicates a poor prognosis regardless of ISS stage, confirming the report by Gkotzamanidou, Terpos, and Dimopoulos et al, and should be included in the definition of stage III disease. Such patients require rapid control of disease with sequential combinations of effective drugs and intensive therapy in order to improve their outcome. [Table: see text]

scholarly journals BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

2012 ◽  
Vol 30 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Kevin B. Kim ◽  
Jeffrey A. Sosman ◽  
John P. Fruehauf ◽  
Gerald P. Linette ◽  
Svetomir N. Markovic ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Elevated Serum ◽  
Serum Lactate ◽  
Primary Objective ◽  
Phase Iii ◽  
Serum Lactate Dehydrogenase ◽  
Double Blind

Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma. Patients and Methods Patients were randomly assigned in a two-to-one ratio to carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m2) and bevacizumab (15 mg/kg; CPB) or placebo (CP) administered intravenously once every 3 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS) and safety. Results Two hundred fourteen patients (73% with M1c disease) were randomly assigned. With a median follow-up of 13 months, median PFS was 4.2 months for the CP arm (n = 71) and 5.6 months for the CPB arm (n = 143; hazard ratio [HR], 0.78; P = .1414). Overall response rates were 16.4% and 25.5%, respectively (P = .1577). With 13-month follow-up, median OS was 8.6 months in the CP arm versus 12.3 months in the CPB arm (HR, 0.67; P = .0366), whereas in an evaluation 4 months later, it was 9.2 versus 12.3 months, respectively (HR, 0.79; P = .1916). In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS were longer in the CPB arm (PFS: 4.4 v 2.7 months; HR, 0.62; OS: 8.5 v 7.5 months; HR, 0.52). No new safety signals were observed. Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting.

Serum Lactate Dehydrogenase is Elevated in Ischemic Acute Tubular Necrosis but Not in Acute Rejection in Kidney Transplant Patients

2016 ◽  
Vol 27 (1) ◽  
pp. 53-57 ◽  
Author(s):  
Hefziba Green ◽  
Ana Tobar ◽  
Anat Gafter-Gvili ◽  
Leonard Leibovici ◽  
Tirza Klein ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Lactate Dehydrogenase ◽  
Acute Rejection ◽  
Acute Tubular Necrosis ◽  
Elevated Serum ◽  
Graft Function ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Antibody Mediated Rejection ◽  
Tubular Necrosis

Background: Serum lactate dehydrogenase (LDH) levels may help to distinguish ischemic acute tubular necrosis (ATN) from acute rejection after kidney transplantation. Methods: All kidney biopsies performed in the years 2010 to 2012 were reviewed. Serum LDH, creatinine level, clinical variables, and presence of donor-specific antibodies were recorded before the biopsy. Results: Overall 150 biopsies were included. Ischemic ATN was diagnosed in 45 biopsies and acute cellular-mediated rejection and/or antibody-mediated rejection in 59 biopsies, 38 of which were accompanied by ATN. Serum LDH was elevated in 23 (51%) of 45 cases with ischemic ATN versus 15 (14%) of 105 cases with other diagnoses ( P < .0001). Median serum LDH was 478 U/L (range 277-2018) for ischemic ATN and 372 U/L (range 191-748) for all other diagnoses ( P < .001). When delayed graft function or primary nonfunctioning grafts were caused by ischemic ATN, serum LDH was elevated in 58% of cases, but when caused by acute rejection, LDH was normal in 88% of cases ( P = .02). Conclusions: There is a strong association between elevated serum LDH 1 to 3 days before performing kidney biopsy and the diagnosis of ischemic ATN after kidney transplantation, especially at the immediate posttransplantation period. Normal serum LDH at this period should raise a suspicion of acute rejection.

scholarly journals Diagnostic Value of Serum Lactate Dehydrogenase Isoenzyme and Amino Acid Patterns in Several Schistosomal and Non-Schistosomal Disorders as Compared to other Biochemical Parameters

1996 ◽  
Vol 13 (1) ◽  
pp. 19-29 ◽  
Author(s):  
Samia A. Ahmed ◽  
Mohamed Z. Gad
Keyword(s):  
Bladder Cancer ◽  
Amino Acid ◽  
Lactate Dehydrogenase ◽  
Biochemical Parameters ◽  
Elevated Serum ◽  
Diagnostic Value ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Control Group ◽  
Ldh Isoenzyme

Serum lactate dehydrogenase (LDH) isoenzyme and amino acid (a. a) patterns were evaluated in comparison to several other biochemical parameters for liver and renal function with the objective of clarifying the differential diagnosis of hepatic disorders and predicting the outcome of schistosomal infection in Egyptian patients. Patients examined included those with complicated hepatic disorders and others with different stages of schistosomal infestation, hepatoma or bladder cancer, in addition to a normal control group. Several biochemical parameters appeared to be useful in establishing consistent differences or similarities between the studied groups. Examples are; elevated serum AST/ AL T ratio and methionine content in chronic schistosomiasis, elevated serum urea/creatinine ratio and leucine content in all schistosomal patients and extremely high levels of N-acetyl-β-D-glucosaminidase (NAG) in the urine of non-schistosomal bladder cancer patients. In addition, characteristic LDH isoenzyme profiles distinguish between the studied groups, in particular separating chronic schistosomiasis from schistosomal bladder cancer and hepatoma from other hepatic disorders.

Sign in / Sign up

Export Citation Format

Share Document